The third-generation CAR-T treatment with CD28 in combination with 4-1BB co-stimulation domains can significantly reduce the incidence of ≥3 grade CRS as compared with CD28 or 4-1BB co-stimulation (Figure 5). This evidence concerns the gene CD28 and congenital rubella syndrome.